Report Code : CVMI2603252601377 | Published Date : March 30, 2025
1 | Market Overview
The global intravenous immunoglobulin (IVIG) market is growing rapidly due to the increasing prevalence of primary and secondary immunodeficiency disorders, autoimmune diseases, and neurological conditions. IVIG is a plasma-derived therapy used to enhance the immune response or suppress abnormal immune activity. It is administered intravenously to treat a wide range of disorders, such as chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barré syndrome, primary immunodeficiencies (PIDs), and idiopathic thrombocytopenic purpura (ITP).
Technological advancements in plasma fractionation, enhanced supply chain logistics, and increasing awareness among healthcare professionals are driving IVIG adoption. Both governments and private organizations are also expanding reimbursement and plasma collection infrastructure.
2 | Market Size and Forecast
Year |
Market Value (USD Billion) |
Notes |
2019 |
9.3 |
Historical baseline |
2024 |
16.4 |
Five-year CAGR 11.4% |
2031 |
34.2 |
Seven-year CAGR 11.2% |
The market is expected to more than double by 2031, driven by therapeutic expansion and a growing base of immunocompromised patients.
3 | Key Market Drivers
- Rising Prevalence of Immunodeficiency and Autoimmune Diseases: Increasing diagnoses of PIDs and CIDP.
- Expanding Use in Neurology and Hematology: IVIG serves as a cornerstone in numerous immune-mediated neurological therapies.
- Plasma Collection Enhancements: Enhancing donor recruitment and plasma fractionation efficiency.
- Favorable Reimbursement Policies: Strong support from payers in North America and parts of Europe.
4 | Market Challenges
- Supply Chain Constraints: Scarcity of plasma and extended manufacturing cycles.
- High treatment cost: IVIG is among the most expensive biologics.
- Stringent Regulatory Compliance: Quality and safety standards for plasma-derived therapies are intricate.
5 | Competitive Landscape
The IVIG market is consolidated, with global leaders in plasma therapeutics dominating production, branding, and distribution.
Market Share Estimates (2024):
Company |
Estimated Market Share |
Key Products |
Takeda Pharmaceuticals |
28% |
Gammagard®, GAMUNEX®-C |
Grifols |
23% |
Flebogamma®, Gamunex®, XEMBIFY® (SC) |
CSL Behring |
21% |
Privigen®, Hizentra® (SC) |
Octapharma |
14% |
Octagam®, Panzyga® |
Others (Kedrion, Biotest, China Biologic) |
14% |
Regional brands and niche formulations |
6 | Market Segmentation
By Indication:
- Primary Immunodeficiency
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain-Barré Syndrome
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others (Kawasaki Disease, Myasthenia Gravis)
By End User:
- Hospitals
- Specialty Clinics
- Home Infusion Centers
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
7 | Strategic Outlook
Market growth will be sustained by next-generation IVIG formulations, subcutaneous alternatives, and strategic investments in expanding the donor network. Companies focusing on product differentiation, digital infusion tracking, and global access programs will drive long-term gains
Reasons To Buy

Scope

Key Players
- CSL Behring
- Grifols
- Takeda
- Octapharma
- Kedrion
- Biotest
- ADMA Biologics
- China Biologic Products
Intravenous Immunoglobulin Market Report
- 1. Intravenous Immunoglobulin Market Research Report
- 1.1 Study Objectives
- 1.2 Intravenous Immunoglobulin Market - Overview
- 1.3 Reason to Read This Report
- 1.4 Methodology and Forecast Analysis
- 2. Intravenous Immunoglobulin Market Research Report - Preface
- 2.1 Intravenous Immunoglobulin Market Research Report – Detailed Scope and Definitions
- 2.1.1 By Indication:
- 2.1.2 By End User:
- 2.1.3 By Region
- 2.1 Intravenous Immunoglobulin Market Research Report – Detailed Scope and Definitions
- 3. Intravenous Immunoglobulin Market Dynamics
- 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
- 3.2. Restraints – By Indication:, By End User:, By Country
- 3.3. Opportunities – By Indication:, By End User:, By Country
- 3.4. Trends – By Indication:, By End User:, By Country
- 3.5. PEST Analysis
- 3.6. Porters Five Rule Analysis
- 3.7. Company’s Share Analysis (CSA) by Region or By Country
- 3.8. Intravenous Immunoglobulin Market Research Report – DROTs Impact Analysis
-
- 4. Intravenous Immunoglobulin Market Research Report, Historic Data 2019 - 2023 and Forecast Analysis Data 2024 - 2031
- 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
- 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
- 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5. Intravenous Immunoglobulin Market, By Indication:, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
- 5.1 Primary Immunodeficiency
- 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.3 Guillain-Barré Syndrome
- 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 5.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.1 Hospitals
- 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.2 Specialty Clinics
- 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.3 Home Infusion Centers
- 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7. Intravenous Immunoglobulin Market Forecast, By Region, 2019 - 2023 and 2024 - 2031 (Market Value, In USD Mn)
- 7.1 North America
- 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.1 North America
- 8. North America Intravenous Immunoglobulin Market Analysis, 2019 - 2023 and Forecast, 2024 - 2031 (Market Value, In USD Mn)
- 8.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 8.1.1 Primary Immunodeficiency
- 8.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 8.1.3 Guillain-Barré Syndrome
- 8.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 8.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 8.2.1 Hospitals
- 8.2.2 Specialty Clinics
- 8.2.3 Home Infusion Centers
- 8.3.1 United States
- 8.3.2 Canada
- 8.4 North America Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
- 8.5 Regional Trends Analysis
- 8.6 North America Intravenous Immunoglobulin Market Research Report - Company Profiles
- 8.6.1 Company 1 (United States)
- 8.6.2 Company 2 (Canada)
- 8.6.3 Company 3 (Canada)
- 9.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 9.1.1 Primary Immunodeficiency
- 9.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 9.1.3 Guillain-Barré Syndrome
- 9.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 9.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 9.2.1 Hospitals
- 9.2.2 Specialty Clinics
- 9.2.3 Home Infusion Centers
- 9.3.1 Germany
- 9.3.2 United Kingdom
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Russia
- 9.4 Europe Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
- 9.5 Regional Trends Analysis
- 9.6 Europe Intravenous Immunoglobulin Market Research Report - Company Profiles
- 9.6.1 Company 1 (Germany)
- 9.6.2 Company 2 (United Kingdom)
- 9.6.3 Company 3 (United Kingdom)
- 10.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 10.1.1 Primary Immunodeficiency
- 10.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 10.1.3 Guillain-Barré Syndrome
- 10.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 10.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 10.2.1 Hospitals
- 10.2.2 Specialty Clinics
- 10.2.3 Home Infusion Centers
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 South Korea
- 10.3.5 Australia & New Zealand
- 10.3.6 ASEAN
- 10.4 Asia-Pacific Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
- 10.5 Regional Trends Analysis
- 10.6 Asia-Pacific Intravenous Immunoglobulin Market Research Report - Company Profiles
- 10.6.1 Company 1 (China)
- 10.6.2 Company 2 (Japan)
- 10.6.3 Company 3 (Japan)
- 11.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 11.1.1 Primary Immunodeficiency
- 11.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 11.1.3 Guillain-Barré Syndrome
- 11.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 11.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 11.2.1 Hospitals
- 11.2.2 Specialty Clinics
- 11.2.3 Home Infusion Centers
- 11.3.1 Brazil
- 11.3.2 Mexico
- 11.3.3 Argentina
- 11.3.4 Peru
- 11.3.5 Colombia
- 11.3.6 Rest of Latin America
- 11.4 Latin America Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
- 11.5 Regional Trends Analysis
- 11.6 Latin America Intravenous Immunoglobulin Market Research Report - Company Profiles
- 11.6.1 Company 1 (Brazil)
- 11.6.2 Company 2 (Mexico)
- 11.6.3 Company 3 (Mexico)
- 12.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 12.1.1 Primary Immunodeficiency
- 12.1.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- 12.1.3 Guillain-Barré Syndrome
- 12.1.4 Idiopathic Thrombocytopenic Purpura (ITP)
- 12.1.5 Others (Kawasaki Disease, Myasthenia Gravis)
- 12.2.1 Hospitals
- 12.2.2 Specialty Clinics
- 12.2.3 Home Infusion Centers
- 12.3.1 Saudi Arabia
- 12.3.2 UAE
- 12.3.3 South Africa
- 12.3.4 Egypt
- 12.3.5 Israel
- 12.3.6 Rest of Middle East and Africa
- 12.4 Middle East and Africa Intravenous Immunoglobulin Market – Opportunity Analysis Index, By Indication:, By End User:, and Country, 2024 - 2031
- 12.5 Regional Trends Analysis
- 12.6 Middle East and Africa Intravenous Immunoglobulin Market Research Report - Company Profiles
- 12.6.1 Company 1 (Saudi Arabia)
- 12.6.2 Company 2 (UAE)
- 12.6.3 Company 3 (UAE)
- 13.1 Strategic Dashboard of Top Market Players
- 13.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)
- 13.2.1 Biotest AG
- 13.2.2 Kedrion Biopharma
- 13.2.3 Grifols S.A.
- 13.2.4 Bio Products Laboratory
- 13.2.5 Takeda Pharmaceutical Company Limited
- 13.2.6 CSL Behring
- 13.2.7 Octapharma AG
- 13.2.8 Baxter International Inc.
- 13.2.9 LFB Group
- 13.2.10 China Biologic Products Holdings
- 13.2.11 Shanghai RAAS Blood Products
- 13.2.12 Hualan Biological Engineering
- 13.2.13 ADMA Biologics
- 13.2.14 Emergent BioSolutions
- 13.2.15 Kamada Ltd.
- 8.1 By Indication: Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 14. Data Collection Method and Research Approach
- 15. Principal Presumptions and Acronyms